Education
About Us
Working with TipRanks
Follow Us
AXIM Biotechnologies Inc (AXIM)
OTHER OTC:AXIM
AXIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume359.42K
Average Volume (3M)338.19K
Market Cap
$1.41M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding301,958,830
10 Day Avg. Volume338,189
30 Day Avg. Volume338,189
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AXIM Biotechnologies News
AXIM FAQ
What was AXIM Biotechnologies Inc’s price range in the past 12 months?
AXIM Biotechnologies Inc lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is AXIM Biotechnologies Inc’s market cap?
AXIM Biotechnologies Inc’s market cap is $1.41M.
When is AXIM Biotechnologies Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AXIM Biotechnologies Inc’s earnings last quarter?
Currently, no data Available
Is AXIM Biotechnologies Inc overvalued?
According to Wall Street analysts AXIM Biotechnologies Inc’s price is currently Overvalued.
Does AXIM Biotechnologies Inc pay dividends?
AXIM Biotechnologies Inc does not currently pay dividends.
What is AXIM Biotechnologies Inc’s EPS estimate?
AXIM Biotechnologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AXIM Biotechnologies Inc have?
AXIM Biotechnologies Inc has 301,958,830 shares outstanding.
What happened to AXIM Biotechnologies Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AXIM Biotechnologies Inc?
Currently, no hedge funds are holding shares in AXIM
Company Description
AXIM Biotechnologies Inc
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
AXIM Biotechnologies (AXIM) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
TNF Pharmaceuticals
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Protagenic Therapeutics
―
Onconetix
―
Ownership Overview
Options Prices
Currently, No data available
---